Skip to main content
Journal cover image

Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).

Publication ,  Journal Article
Kushnir, CL; Angarita, AM; Havrilesky, LJ; Thompson, S; Spahlinger, D; Sinno, AK; Tanner, EJ; Secord, AA; Roche, KL; Stone, RL; Fader, AN
Published in: Gynecol Oncol
June 2015

OBJECTIVE: The study objective was to examine the safety and cost savings of selective cardiac surveillance (CS) during treatment with pegylated liposomal doxorubicin (PLD). METHODS: A retrospective, dual institution study of women receiving PLD for the treatment of a gynecologic malignancy was performed. The study period was 2002-2014. At both institutions, a selective strategy for CS was implemented in which only high-risk women with a cardiac history or with symptoms suggestive of cardiac toxicity during PLD treatment underwent a cardiac evaluation. Patient demographics, clinical and treatment history were evaluated. Cost analyses were performed utilizing professional/technical fee rates for echocardiogram and multi-gated acquisition scan for each state. RESULTS: PLD was administered in 184 women. The mean patient age was 62.7years, and 79% were treated for recurrent ovarian or peritoneal carcinoma. The median cumulative administered dose of PLD was 300mg/m(2); 24 received >550mg/m(2). The median follow-up time was 20months. Of the 184 patients, the majority (n=157, 85.3%) did not undergo either an initial cardiac evaluation or surveillance during or post-PLD treatment. Fifty-three patients considered high risk for anthracycline-induced cardiotoxicity underwent CS. Only three patients (1.6%) in the entire cohort developed CHF that was possibly related to PLD treatment; all had significant pre-existing cardiac risk factors. Selective instead of routine use of CS in the study population resulted in a cost savings of $182,552.28. CONCLUSION: Utilizing cardiac surveillance in select women undergoing PLD treatment for gynecologic malignancies resulted in significant health care cost savings without adversely impacting clinical outcomes.

Duke Scholars

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

June 2015

Volume

137

Issue

3

Start / End Page

503 / 507

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Echocardiography
  • Doxorubicin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kushnir, C. L., Angarita, A. M., Havrilesky, L. J., Thompson, S., Spahlinger, D., Sinno, A. K., … Fader, A. N. (2015). Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol, 137(3), 503–507. https://doi.org/10.1016/j.ygyno.2015.02.020
Kushnir, C. L., A. M. Angarita, L. J. Havrilesky, S. Thompson, D. Spahlinger, A. K. Sinno, E. J. Tanner, et al. “Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).Gynecol Oncol 137, no. 3 (June 2015): 503–7. https://doi.org/10.1016/j.ygyno.2015.02.020.
Kushnir CL, Angarita AM, Havrilesky LJ, Thompson S, Spahlinger D, Sinno AK, et al. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol. 2015 Jun;137(3):503–7.
Kushnir, C. L., et al. “Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).Gynecol Oncol, vol. 137, no. 3, June 2015, pp. 503–07. Pubmed, doi:10.1016/j.ygyno.2015.02.020.
Kushnir CL, Angarita AM, Havrilesky LJ, Thompson S, Spahlinger D, Sinno AK, Tanner EJ, Secord AA, Roche KL, Stone RL, Fader AN. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol. 2015 Jun;137(3):503–507.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

June 2015

Volume

137

Issue

3

Start / End Page

503 / 507

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Echocardiography
  • Doxorubicin